MedTrace Logo

The Effectiveness of Blastocentesis Versus Trophectoderm Biopsy

NCT02915276 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2016-09-27

No results posted yet for this study

Summary

For the purpose of this study, the investigators will perform the removal of trophectoderm (TE) the cells as required for the purpose of pre-implantation genetic screening, in order to perform the genetic analysis. Additionally, the investigators will remove the blastocoelic fluid (BF) and perform additional genetic analysis on the embryo in order to determine the agreement of the genetics results between TE cells and BF.

Conditions

  • Abnormal Karyotype

Interventions

PROCEDURE

Blastocentisis

Removal of blastocoelic fluid from the blastocoelic cavity

PROCEDURE

Trophectoderm biopsy

Removal of trophectoderm cells from the blastocyst

Sponsors & Collaborators

  • Center for Reproductive an Genetic Health

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2017-03-31
Completion
2017-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02915276 on ClinicalTrials.gov